Take Homes in Lung Cancer

Take Homes in Lung Cancer

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics. Tsuboi reports receiving honoraria from AstraZeneca KK, Boehringer-Ingelheim Japan, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan, Johnson & Johnson Japan, Medtronic Japan, MSD, Ono Pharmaceutical Co., Ltd., Taiho Pharma and Teijin Pharma; and research grant/funding to institution from AstraZeneca KK, Boehringer-Ingelheim Japan and MSD.
November 12, 2020
1 min watch
Save

VIDEO: Targeted therapy in lung cancer ‘personalized medicine at its best’

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics. Tsuboi reports receiving honoraria from AstraZeneca KK, Boehringer-Ingelheim Japan, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan, Johnson & Johnson Japan, Medtronic Japan, MSD, Ono Pharmaceutical Co., Ltd., Taiho Pharma and Teijin Pharma; and research grant/funding to institution from AstraZeneca KK, Boehringer-Ingelheim Japan and MSD.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, provided a quick rundown of presentations from the Chemotherapy Foundation Symposium that focused on targeted therapy.

According to Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, experts reviewed targeted therapy options for EGFR, BRAF, MET, HER2 and KRAS mutations, and ALK, ROS1, RET and NTRK fusions.

“Truly heralding personalized medicine at its best,” he said.

References:

  • Drilon AE. Targeting ALK, ROS1, RET, and NTRK Fusions. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
  • Horn L. Targeting BRAF, MET, HER2, and KRAS Mutations. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
  • Mok TS. Targeting EGFR-Mutant Lung Cancers. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.